stockrow
Monday 9 November 2026
Export CUVL’s income statement to Excel — free account
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR
CUVL
5.10
0.08
+1.59%
Follow CUVL
Alert me
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LCTX Lineage Cell Therapeutics, Inc. compare | n/m |
| SPRY ARS Pharmaceuticals, Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| QTTB Q32 Bio Inc. compare | 3.1× |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)